The Effects of Intravenous(iv), Subcutaneous (Sc) and Intranasal (In) Administration of 6h-Rh(1–44)mh2 on Growth-Hormone Secretion in Normal Men: Dose-Response Relationships

Colle, M.; Frangin, G.; Auzerie, J; Ruedas, E; Haouche, G; Morre, Michel; Chaussain, J L

doi:10.1203/00006450-198801000-00115

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The confirmation of our earlier demonstration of the efficacy of intranasal GHRH (1-44) administration on GH re lease [12] is thus encouraging. In that study, approxi mately 15-and 40-fold increases in GHRH dosages were required for subcutaneous and intranasal administration, respectively, in order to give comparable responses to intravenous GHRH.…”

Section: Discussionsupporting

confidence: 75%

“…Early pilot studies using intranasal GHRH in doses of 100, 250, 500, 1,000, and 2,000 pg showed the efficacy of these doses in stimulating endogenous GH release [12], The highest dose of GHRH used (2,000 pg) gave a similar dynamic GH response to an 80-pg intravenous dose. From these studies, it was possible to calculate a single mean effective dose required to raise the GH peak to more than 15 ng/ml (1,000 pg), as well as determining the effects of the GHRH vehicle.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Placebo-Controlled Trial of Intranasal Growth Hormone-Releasing Hormone [GHRH(l-44)-NH<sub>2</sub>] Administration in Normal Young Adults

Colle¹,

Frangin

Auzerie

et al. 1990

Horm Res

View full text Add to dashboard Cite

Growth hormone-releasing hormone, GHRH(l-44), was administered intranasally to 16 healthy young adult male volunteers in a placebo-controlled study using a dose of 1,000 µg dissolved in two different solvent vehicles: water alone and water with the surface tension-lowering agent Tween 80 (0.12%). The growth hormone (GH)-releasing effects of intranasal GHRH as well as that of the vehicle were established and compared to the effects of 80 µg intravenous GHRH. Plasma GH response was assessed by frequent blood sampling over an 180-min period, using both peak response and area under the curve (AUC). The results show that the GH-releasing effects of intranasal GHRH are comparable whichever vehicle is used, and are similar, with the dose of 1,000 µg, to the response obtained following the administration of 80 µg intravenous GHRH. Peak GH responses to GHRH (means ± SEM) were 25.6 ± 4.2 ng/ml (1,000 µg GHRH with water), 32.9 ± 9.1 ng/ml (1,000 µg with water plus Tween 80) and 36.3 ± 7.8 ng/ml (80 µg i.v. administration) (not significant). There was no significant GH response to placebo. Mean peak GH responses occurred after approximately 30 min in all three active treatments (29.2 ± 2.7, 33.9 ± 3.2 and 30.9 ± 3.9 min, respectively). The AUC values (ng·min· ml”1) were not statistically different: 1,914.4 ± 386.7 (water), 2,176.2 ± 599.9 (water plus Tween 80) and 2,419.2 ± 506.9 (i.v.) (not significant). Intranasal GHRH administration was well tolerated in all subjects. Occasional local reactions consisted of a prickly sensation in the nostrils or sneezing irrespective of the vehicle used. Long-term tolerance should be established before considering trial of intranasal GHRH administration in the treatment of GH-deficient children.

show abstract

Section: Discussionsupporting

confidence: 75%

Section: Introductionmentioning

confidence: 99%